Effective management of COPD in primary care - the role of long-acting beta agonist/inhaled corticosteroid combination therapy

Primary Care Respiratory Journal

Volumn 15, Issue 3, 2006, Pages 143-151

  Reid, Jim ^b  

^a Onno)   (Netherlands)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

2 agonists; COPD; Functional status exacerbations; Inhaled steroids

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; TRIAMCINOLONE;

BONE DENSITY; BONE DESTRUCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; HIP FRACTURE; HUMAN; LUNG DISEASE; MUSCLE ATROPHY; MUSCLE TONE; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW; SPUTUM ANALYSIS; THROAT IRRITATION; THRUSH;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; DRUG THERAPY, COMBINATION; HEALTH STATUS; HUMANS; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33744511031     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.1016/j.pcrj.2006.02.007     Document Type: Review

References (67)

1. BTS. British Thoracic Society. The British Guidelines on Asthma Management 1995: review and position statement. Thorax 55 (1997) S1-S21
2. GOLD. Global initiative for chronic obstructive lung disease: global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163 (2001) 1256-1276
3. Snider G.L. Defining chronic obstructive pulmonary disease. In: Calverley P., and Pride N. (Eds). Chronic Obstructive Pulmonary Disease (1995), Chapman and Hall, London
4. Rodriguez-Roisin R. Pulmonary gas exchange in acute respiratory failure. Eur J Anaesthesiol 11 (1994) 5-13
5. Wedzicha J.A. Exacerbations: etiology and pathophysiologic mechanisms. Chest 121 (2002) 136S-141S
6. Agusti A.G., Noguera A., Sauleda J., Sala E., Pons J., and Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 21 (2003) 347-360
7. Agusti A.G. COPD, a multicomponent disease: implications for management. Respir Med 99 (2005) 670-682
8. Wright J.L., Lawson L., Pare P.D., et al. The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease. The effect of oxygen and exercise. Am Rev Respir Dis 128 (1983) 702-707
9. Cosio M.G., Majo J., and Cosio M.G. Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest 121 (2002) 160S-165S
10. Rogers D.F. Mucus hypersecretion in chronic obstructive pulmonary disease. Novartis Found Symp 234 (2001) 65-77 discussion 77-83
11. Smaldone G.C., Foster W.M., O'Riordan T.G., Messina M.S., Perry R.J., and Langenback E.G. Regional impairment of mucociliary clearance in chronic obstructive pulmonary disease. Chest 103 (1993) 1390-1396
12. Anthonisen N.R., Connett J.E., Kiley J.P., et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 272 (1994) 1497-1505
13. Wagena EJ, Knipschild P, Huibers MJH, Wouters EFM, Schayck CP van. The efficacy of bupropion and notriptyline for smoking cessation among people who are at risk for or have COPD: a randomized, placebo-controlled trial. Arch Intern Med 2005;165:2286-92.
14. Chavannes N., Vollenberg J.J., van Schayck C.P., and Wouters E.F. Effects of physical activity in mild to moderate COPD: a systematic review. Br J Gen Pract 52 (2002) 574-578
15. Decramer M., Gosselink R., Bartsch P., et al. Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004. Thorax 60 (2005) 343-349
16. Casaburi R., Mahler D.A., Jones P.W., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19 (2002) 217-224
17. O'Donnell D.E., Fluge T., Gerken F., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23 (2004) 832-840
18. Vincken W., van Noord J.A., Greefhorst A.P., et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 19 (2002) 209-216
19. Boyd G., Morice A.H., Pounsford J.C., Siebert M., Peslis N., and Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 10 (1997) 815-821
20. Ramirez-Venegas A., Ward J., Lentine T., and Mahler D.A. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 112 (1997) 336-340
21. Cazzola M., Matera M.G., Santangelo G., Vinciguerra A., Rossi F., and D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 89 (1995) 357-362
22. Aalbers R., Ayres J., Backer V., et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 19 (2002) 936-943
23. Mahler D.A., Donohue J.F., Barbee R.A., et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 115 (1999) 957-965
24. Dahl R., Greefhorst L.A., Nowak D., et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 778-784
25. GOLD. Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease, Updated 2004. National Institutes of Health. National Heart, Lung and Blood Institute 2004: www.goldcopd.com.
26. Celli B.R., and MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004) 932-946
27. Dougherty J.A., Didur B.L., and Aboussouan L.S. Long-acting inhaled beta 2-agonists for stable COPD. Ann Pharmacother 37 (2003) 1247-1255
28. Sin D.D., McAlister F.A., Man S.F., and Anthonisen N.R. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 290 (2003) 2301-2312
29. Mahler D.A., Wire P., Horstman D., et al. Effectiveness of Fluticasone Propionate and Salmeterol Combination Delivered via the Diskus Device in the Treatment of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 166 (2002) 1084-1091
30. Barnes P.J. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161 (2000) 342-344 discussion 344
31. Calverley P.M. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161 (2000) 341-342 discussion 344
32. van Schayck C.P., van Grunsven P.M., and Dekhuijzen P.N. Do patients with COPD benefit from treatment with inhaled corticosteroids?. Eur Respir J 9 (1996) 1969-1972
33. Weiner P., Weiner M., Rabner M., Waizman J., Magadle R., and Zamir D. The response to inhaled and oral steroids in patients with stable chronic obstructive pulmonary disease. J Intern Med 245 (1999) 83-89
34. Paggiaro P.L., Dahle R., Bakran I., Frith L., Hollingworth K., and Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 351 (1998) 773-780
35. Pauwels R.A., Lofdahl C.G., Laitinen L.A., et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 340 (1999) 1948-1953
36. Burge P.S., Calverley P.M., Jones P.W., Spencer S., Anderson J.A., and Maslen T.K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 320 (2000) 1297-1303
37. Calverley P., Pauwels R., Vestbo J., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361 (2003) 449-456
38. Calverley P.M., Boonsawat W., Cseke Z., Zhong N., Peterson S., and Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22 (2003) 912-919
39. Szafranski W., Cukier A., Ramirez A., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21 (2003) 74-81
40. Sin D.D., Wu L., Anderson J., et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 60 (2005) 992-997
41. Hanania N.A., Darken P., Horstman D., et al. The efficacy and safety of fluticasone propionate 250 mcg/salmeterol 50 mcg combined in the discus inhaler for the treatment of chronic obstrctive pulmonary disease. Chest 124 (2003) 834-843
42. Dal Negro R.W., Pomari C., Tognella S., and Micheletto C. Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulm Pharmacol Ther 16 (2003) 241-246
43. Vestbo J., Pauwels R., Anderson J.A., Jones P., and Calverley P. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax 60 (2005) 301-304
44. Wouters E.F., Postma D.S., Fokkens B., et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 60 (2005) 480-487
45. Donohue J.F., Kalberg C., Emmett A., Merchant K., and Knobil K. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. Treat Respir Med 3 (2004) 173-181
46. Make B., Hanania N.A., ZuWallack R., et al. The efficacy and safety of inhaled fluticasone propionate/salmeterol compared with ipratropium/albuterol in the treatment of COPD. Clinical Therapeutics 27 5 (2005) 532-542
47. Jones P.W., Quïrk F., Baveystock C.M., and Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 145 (1992) 1321-1327
48. Guyatt G.H., Berman L.B., Townsend M., Pugsley S.O., and Chambers L.W. A measure of quality of life for clinical trials in chronic lung disease. Thorax 42 (1987) 773-778
49. Jaeschke R., Singer J., and Guyatt G.H. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 10 (1989) 407-415
50. Turato G., Zuin R., and Saetta M. Pathogenesis and pathology of COPD. Respiration 68 (2001) 117-128
51. Groenewegen K.H., Schols A.M., and Wouters E.F. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 124 (2003) 459-467
52. Patil S.P., Krishnan J.A., Lechtzin N., and Diette G.B. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 163 (2003) 1180-1186
53. Seneff M.G., Wagner D.P., Wagner R.P., Zimmerman J.E., and Knaus W.A. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 274 (1995) 1855-1857
54. Donaldson G.C., Seemungal T.A., Bhowmik A., and Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57 (2002) 847-852
55. GOLD. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur Respir J 22 (2003) 1-2
56. Sin D.D., and Tu J.V. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 580-584
57. Soriano J.B., Vestbo J., Pride N.B., Kiri V., Maden C., and Maier W.C. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 20 (2002) 819-825
58. Soriano J.B., Kiri V.A., Pride N.B., and Vestbo J. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2 (2003) 67-74
59. Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 24 (2004) 206-210
60. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 343 (2000) 1902-1909
61. Hubbard R.B., Smith C.J., Smeeth L., Harrison T.W., and Tattersfield A.E. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 166 (2002) 1563-1566
62. Halpern M.T., Schmier J.K., Van Kerkhove M.D., Watkins M., and Kalberg C.J. Impact of long-term inhaled corticosteroid therapy on bone mineral density: results of a meta-analysis. Ann Allergy Asthma Immunol 92 (2004) 201-207 quiz 207-8, 267
63. Johannes C.B., Schneider G.A., Dube T.J., Alfredson T.D., Davis K.J., and Walker A.M. The risk of nonvertebral fracture related to inhaled corticosteroid exposure among adults with chronic respiratory disease. Chest 127 (2005) 89-97
64. Suissa S., Baltzan M., Kremer R., and Ernst P. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 169 (2004) 83-88
65. Malolepszy J., Boszormenyi Nagy G., Selroos O., Larsso P., and Brander R. Safety of formoterol Turbuhaler at cumulative dose of 90 microg in patients with acute bronchial obstruction. Eur Respir J 18 (2001) 928-934
66. Kempsford R., Handel M., Mehta R., De Silva M., and Daley-Yates P. Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects. Respir Med 99 Suppl A (2005) S11-S19
67. Fenton C., and Keating G.M. Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease. Drugs 64 (2004) 1975-1996